Business Context and Reporting Period
Daré Bioscience, Inc. (DARE) filed a Form 8-K Current Report dated May 7, 2026, covering events occurring on May 1, 4, 5, and 6, 2026. The company, incorporated in Delaware and listed on the Nasdaq Capital Market, is an emerging growth company focused on biotechnology.
Key Financial Metrics and Capital Structure
This filing reports on a specific equity financing event rather than general operating performance. Key metrics related to the transaction include:
- Offering Type: Regulation A offering of Investor Units.
- Units Issued: 195,010 Investor Units.
- Offering Price: $5.00 per Investor Unit.
- Components: Each unit consists of one share of Series A Convertible Preferred Stock and two warrants to purchase one share of common stock.
- Warrant Coverage: Warrants issued cover up to 390,020 shares of common stock.
- Capital Raised: Approximately $975,050 (195,010 units x $5.00).
The filing text does not provide clear values for revenue, profit, cash flow, operating margins, total debt, or liquidity positions outside of this specific transaction.
Material Changes
The material change reported is the completion of closings for a previously announced equity offering. The company issued 195,010 shares of Series A Convertible Preferred Stock and associated warrants, increasing its capital base and potential future common stock dilution upon conversion or exercise.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure of the equity issuance. The offering was conducted pursuant to a Form 1-A offering statement qualified by the SEC on April 1, 2026. Terms regarding conversion and exercise were previously disclosed in an 8-K filed on January 29, 2026.
Investor Verification Checklist
- Verify the total aggregate amount raised in the full Regulation A offering, as this filing covers only a portion of the authorized 4,854,000 units.
- Review the January 29, 2026, Form 8-K for detailed terms of the Series A Preferred Stock conversion and warrant exercise.
- Confirm the current cash position and burn rate to assess the runway provided by this $975,050 capital raise.
- Check for any subsequent filings regarding the remaining unsold units from the authorized offering.